LOS ANGELES, Nov. 3, 2016 /PRNewswire/ -- Conference Series has been instrumental in conducting international metabolomics and proteomics meetings for seven years, and very excited to expand Europe, America and Asia Pacific continents. Previous meetings were held in major cities like San Francisco, Tokyo, Madrid, Toronto, Hyderabad and Berlin, with success the meetings again scheduled in three continents. 8 thMetabolomics Meeting to be held during May 11-13, 2017 at Singapore, Asia. 9 th Analytical Metabolomics Meeting scheduled in Netherlands, Europe. 10 th Conference and Exhibition on Metabolomics planned to be conducted at Baltimore during October 19-20, 2017. 8 th International Conference on Proteomics and Bioinformatics, to be held during May 22-24, 2017 in Osaka, Japan. In Europe, Paris chosen for 9 th Proteomics Meeting during October 23-25, 2017 and 10 th Meeting scheduled in United States. The Global Proteomics business sector is fast emerging globally and expected to reach $2,100 Million by 2019, with CAGR of 8.39% during 2014-2019. North America is pioneer with 42% of market share; followed by Europe with an offer of 38%.The Asia-Pacific's business sector is relied to develop at a CAGR of 23% amid the gauge period. Japan is the second largest life sciences market in the world after the United States. According to Data Monitor, Japanese biotechnology market is expected to grow from $43.3 billion in 2013 to $53.8 billion by 2017. The global metabolomics market was valued at $712 million in 2012 and is expect to reach $1.4 billion by 2017, at a CAGR of 14.2%. Factors like increased scope of toxicological studies, clinical trials; rise in awareness for health & government and institution funds for research have immensely contributed for the rising demand for the metabolomics market. North America is the market leader with a share of ~42% of the global market, followed by Europe with a share of ~38%. The presence of a large number of analytical equipment manufacturers has contributed significantly to the North American and European metabolomics market. However, the Asia-Pacific region represents a significant growth opportunity for the metabolomics market during the forecast period of 2014 to 2019. "We believe Metabolomics and proteomics are poised for disruption and the global demand for emerging -omics healthcare techniques will grow virtually inelastic as an indispensable spend. We've observed enormous growth in the areas of metabolomics and proteomics from last one decade and remain interested in this type of emerging markets" says Dr Srinubabu Gedela, CEO of OMICS International. Everyone interested in the future of emerging -omics healthcare techniques majorly in metabolomics and proteomics is encouraged to attend. Connect with our social network pages to get regular industry updates.